CN114795402A - 具有平移刻划线的刻划球囊 - Google Patents
具有平移刻划线的刻划球囊 Download PDFInfo
- Publication number
- CN114795402A CN114795402A CN202210438822.2A CN202210438822A CN114795402A CN 114795402 A CN114795402 A CN 114795402A CN 202210438822 A CN202210438822 A CN 202210438822A CN 114795402 A CN114795402 A CN 114795402A
- Authority
- CN
- China
- Prior art keywords
- shaft
- lumen
- spring
- hub
- score line
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000642 polymer Polymers 0.000 claims description 5
- 238000004026 adhesive bonding Methods 0.000 claims description 3
- 238000003466 welding Methods 0.000 claims description 3
- 238000005219 brazing Methods 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- -1 isonicotin Chemical compound 0.000 description 58
- 230000003902 lesion Effects 0.000 description 24
- 230000007704 transition Effects 0.000 description 13
- 239000002253 acid Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
- 239000012530 fluid Substances 0.000 description 5
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 4
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 4
- 239000000730 antalgic agent Substances 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 229960000482 pethidine Drugs 0.000 description 4
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 4
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 3
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 3
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 3
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 3
- 229960000616 diflunisal Drugs 0.000 description 3
- 229960000192 felbinac Drugs 0.000 description 3
- 229960002390 flurbiprofen Drugs 0.000 description 3
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 3
- 229960004752 ketorolac Drugs 0.000 description 3
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 3
- 229960003406 levorphanol Drugs 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229960005181 morphine Drugs 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 2
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 2
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 2
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 2
- FMBVHKPWDJQLNO-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-5-nitroindazole Chemical compound N1=CC2=CC([N+](=O)[O-])=CC=C2N1CC1=CC=CC(F)=C1 FMBVHKPWDJQLNO-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- ANMLJLFWUCQGKZ-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]-3-pyridinecarboxylic acid (3-oxo-1H-isobenzofuran-1-yl) ester Chemical compound FC(F)(F)C1=CC=CC(NC=2C(=CC=CN=2)C(=O)OC2C3=CC=CC=C3C(=O)O2)=C1 ANMLJLFWUCQGKZ-UHFFFAOYSA-N 0.000 description 2
- JJBCTCGUOQYZHK-ZSCHJXSPSA-N 2-acetyloxybenzoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.CC(=O)OC1=CC=CC=C1C(O)=O JJBCTCGUOQYZHK-ZSCHJXSPSA-N 0.000 description 2
- XCHHJFVNQPPLJK-UHFFFAOYSA-N 2-carboxyphenolate;1h-imidazol-1-ium Chemical compound C1=CNC=N1.OC(=O)C1=CC=CC=C1O XCHHJFVNQPPLJK-UHFFFAOYSA-N 0.000 description 2
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 2
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 229920002614 Polyether block amide Polymers 0.000 description 2
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 2
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 2
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 229960005142 alclofenac Drugs 0.000 description 2
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- HYJSGOXICXYZGS-UHFFFAOYSA-N benazolin Chemical compound C1=CC=C2SC(=O)N(CC(=O)O)C2=C1Cl HYJSGOXICXYZGS-UHFFFAOYSA-N 0.000 description 2
- 229960005430 benoxaprofen Drugs 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 229960000962 bufexamac Drugs 0.000 description 2
- MXJWRABVEGLYDG-UHFFFAOYSA-N bufexamac Chemical compound CCCCOC1=CC=C(CC(=O)NO)C=C1 MXJWRABVEGLYDG-UHFFFAOYSA-N 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960001985 dextromethorphan Drugs 0.000 description 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960003976 etidocaine Drugs 0.000 description 2
- 229960005293 etodolac Drugs 0.000 description 2
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 2
- 229960001419 fenoprofen Drugs 0.000 description 2
- 229960004369 flufenamic acid Drugs 0.000 description 2
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960005219 gentisic acid Drugs 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960004769 imidazole salicylate Drugs 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 229960004187 indoprofen Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 229960002373 loxoprofen Drugs 0.000 description 2
- YMBXTVYHTMGZDW-UHFFFAOYSA-N loxoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910001092 metal group alloy Inorganic materials 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 229960002939 metizoline Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229950007856 mofetil Drugs 0.000 description 2
- 229960000938 nalorphine Drugs 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- CMHHMUWAYWTMGS-UHFFFAOYSA-N oxybuprocaine Chemical compound CCCCOC1=CC(C(=O)OCCN(CC)CC)=CC=C1N CMHHMUWAYWTMGS-UHFFFAOYSA-N 0.000 description 2
- 229960003502 oxybuprocaine Drugs 0.000 description 2
- 229960000649 oxyphenbutazone Drugs 0.000 description 2
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229960003893 phenacetin Drugs 0.000 description 2
- PSBAIJVSCTZDDB-UHFFFAOYSA-N phenyl acetylsalicylate Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 PSBAIJVSCTZDDB-UHFFFAOYSA-N 0.000 description 2
- 229950009058 phenyl acetylsalicylate Drugs 0.000 description 2
- 229960000969 phenyl salicylate Drugs 0.000 description 2
- 229960003581 pyridoxal Drugs 0.000 description 2
- 235000008164 pyridoxal Nutrition 0.000 description 2
- 239000011674 pyridoxal Substances 0.000 description 2
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 2
- 229960000581 salicylamide Drugs 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 229960000953 salsalate Drugs 0.000 description 2
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 2
- 229960004492 suprofen Drugs 0.000 description 2
- 229960005262 talniflumate Drugs 0.000 description 2
- 229960002871 tenoxicam Drugs 0.000 description 2
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 2
- AGGKEGLBGGJEBZ-UHFFFAOYSA-N tetramethylenedisulfotetramine Chemical compound C1N(S2(=O)=O)CN3S(=O)(=O)N1CN2C3 AGGKEGLBGGJEBZ-UHFFFAOYSA-N 0.000 description 2
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 2
- 229960002905 tolfenamic acid Drugs 0.000 description 2
- 229960001017 tolmetin Drugs 0.000 description 2
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 2
- 229960003500 triclosan Drugs 0.000 description 2
- 229960003414 zomepirac Drugs 0.000 description 2
- ZXVNMYWKKDOREA-UHFFFAOYSA-N zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 description 2
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 description 1
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- BCXHDORHMMZBBZ-DORFAMGDSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;sulfuric acid Chemical compound OS(O)(=O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC BCXHDORHMMZBBZ-DORFAMGDSA-N 0.000 description 1
- QHGUCRYDKWKLMG-QMMMGPOBSA-N (R)-octopamine Chemical compound NC[C@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-QMMMGPOBSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 1
- PCKNFPQPGUWFHO-SXBRIOAWSA-N (Z)-flucycloxuron Chemical compound FC1=CC=CC(F)=C1C(=O)NC(=O)NC(C=C1)=CC=C1CO\N=C(C=1C=CC(Cl)=CC=1)\C1CC1 PCKNFPQPGUWFHO-SXBRIOAWSA-N 0.000 description 1
- MAYUSTFJKJSJNC-DSXUQNDKSA-N (r)-[(2s,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1O.C([C@H]([C@H](C1)C=C)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 MAYUSTFJKJSJNC-DSXUQNDKSA-N 0.000 description 1
- ZKNJEOBYOLUGKJ-ALCCZGGFSA-N (z)-2-propylpent-2-enoic acid Chemical compound CCC\C(C(O)=O)=C\CC ZKNJEOBYOLUGKJ-ALCCZGGFSA-N 0.000 description 1
- QLAJNZSPVITUCQ-UHFFFAOYSA-N 1,3,2-dioxathietane 2,2-dioxide Chemical compound O=S1(=O)OCO1 QLAJNZSPVITUCQ-UHFFFAOYSA-N 0.000 description 1
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
- WQAQKERCWPUIMH-UHFFFAOYSA-N 1,5-dimethyl-2-phenylpyrazol-3-one;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1O.CN1C(C)=CC(=O)N1C1=CC=CC=C1 WQAQKERCWPUIMH-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- NDVAMUMVOJRAJV-UHFFFAOYSA-N 10h-phenanthren-9-one Chemical compound C1=CC=C2C(=O)CC3=CC=CC=C3C2=C1 NDVAMUMVOJRAJV-UHFFFAOYSA-N 0.000 description 1
- WKQCPUMQBMFPLC-ZWFCQKKLSA-N 11beta,21-Dihydroxypregn-4-ene-3,20-dione 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O WKQCPUMQBMFPLC-ZWFCQKKLSA-N 0.000 description 1
- SBNOTUDDIXOFSN-UHFFFAOYSA-N 1h-indole-2-carbaldehyde Chemical class C1=CC=C2NC(C=O)=CC2=C1 SBNOTUDDIXOFSN-UHFFFAOYSA-N 0.000 description 1
- WZQHUXOIBFWXDT-UHFFFAOYSA-N 2-(diethylamino)ethyl 5-(butylamino)-2-hydroxybenzoate;hydrochloride Chemical compound Cl.CCCCNC1=CC=C(O)C(C(=O)OCCN(CC)CC)=C1 WZQHUXOIBFWXDT-UHFFFAOYSA-N 0.000 description 1
- DDSFKIFGAPZBSR-UHFFFAOYSA-N 2-[(2-acetyloxyphenyl)-oxomethoxy]benzoic acid Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC1=CC=CC=C1C(O)=O DDSFKIFGAPZBSR-UHFFFAOYSA-N 0.000 description 1
- XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 description 1
- MPPOHAUSNPTFAJ-UHFFFAOYSA-N 2-[4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy]propanoic acid Chemical compound C1=CC(OC(C)C(O)=O)=CC=C1OC1=NC2=CC=C(Cl)C=C2O1 MPPOHAUSNPTFAJ-UHFFFAOYSA-N 0.000 description 1
- BURBNIPKSRJAIQ-UHFFFAOYSA-N 2-azaniumyl-3-[3-(trifluoromethyl)phenyl]propanoate Chemical compound OC(=O)C(N)CC1=CC=CC(C(F)(F)F)=C1 BURBNIPKSRJAIQ-UHFFFAOYSA-N 0.000 description 1
- MTFCPNHRBINLRQ-UHFFFAOYSA-N 2-benzoyloxypropyl(cyclohexyl)azanium;chloride Chemical compound Cl.C=1C=CC=CC=1C(=O)OC(C)CNC1CCCCC1 MTFCPNHRBINLRQ-UHFFFAOYSA-N 0.000 description 1
- MECVOSKQBMPUFG-UHFFFAOYSA-N 2-carboxyphenolate;morpholin-4-ium Chemical compound C1COCCN1.OC(=O)C1=CC=CC=C1O MECVOSKQBMPUFG-UHFFFAOYSA-N 0.000 description 1
- GXEUNRBWEAIPCN-UHFFFAOYSA-N 2-chloro-2-(3-chloro-4-cyclohexylphenyl)acetic acid Chemical compound ClC1=CC(C(Cl)C(=O)O)=CC=C1C1CCCCC1 GXEUNRBWEAIPCN-UHFFFAOYSA-N 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 1
- KPNIMNIOYJSWEM-UHFFFAOYSA-N 2-ethyl-4-methyl-2-phenylpentanoic acid Chemical compound CC(C)CC(CC)(C(O)=O)C1=CC=CC=C1 KPNIMNIOYJSWEM-UHFFFAOYSA-N 0.000 description 1
- BFJSDDYECHPBIO-UHFFFAOYSA-N 2-hydroxybenzoic acid;sulfuric acid Chemical compound OS(O)(=O)=O.OC(=O)C1=CC=CC=C1O BFJSDDYECHPBIO-UHFFFAOYSA-N 0.000 description 1
- UJABSZITRMATFL-UHFFFAOYSA-N 2-methyl-5-phenylfuran-3-carbonyl chloride Chemical compound ClC(=O)C1=C(C)OC(C=2C=CC=CC=2)=C1 UJABSZITRMATFL-UHFFFAOYSA-N 0.000 description 1
- PUYOAVGNCWPANW-UHFFFAOYSA-N 2-methylpropyl 4-aminobenzoate Chemical compound CC(C)COC(=O)C1=CC=C(N)C=C1 PUYOAVGNCWPANW-UHFFFAOYSA-N 0.000 description 1
- OLUUSIGKTFFDPM-UHFFFAOYSA-N 2h-oxazine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CON1 OLUUSIGKTFFDPM-UHFFFAOYSA-N 0.000 description 1
- RJDZFUUSXRDFCZ-UHFFFAOYSA-N 2h-oxazocine Chemical compound C1=CC=CONC=C1 RJDZFUUSXRDFCZ-UHFFFAOYSA-N 0.000 description 1
- LORDFXWUHHSAQU-UHFFFAOYSA-N 3,4,5-trimethoxybenzoic acid [2-(dimethylamino)-2-phenylbutyl] ester Chemical compound C=1C=CC=CC=1C(CC)(N(C)C)COC(=O)C1=CC(OC)=C(OC)C(OC)=C1 LORDFXWUHHSAQU-UHFFFAOYSA-N 0.000 description 1
- VYVKHNNGDFVQGA-UHFFFAOYSA-N 3,4-dimethoxybenzoic acid 4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butyl ester Chemical compound C=1C=C(OC)C=CC=1CC(C)N(CC)CCCCOC(=O)C1=CC=C(OC)C(OC)=C1 VYVKHNNGDFVQGA-UHFFFAOYSA-N 0.000 description 1
- SZQBFYIWWMWHDF-UHFFFAOYSA-N 3-(3-phenylphenyl)propan-1-amine Chemical compound NCCCC1=CC=CC(C=2C=CC=CC=2)=C1 SZQBFYIWWMWHDF-UHFFFAOYSA-N 0.000 description 1
- HNPVERUJGFNNRV-UHFFFAOYSA-N 3-iodophthalic acid Chemical compound OC(=O)C1=CC=CC(I)=C1C(O)=O HNPVERUJGFNNRV-UHFFFAOYSA-N 0.000 description 1
- XQJMXPAEFMWDOZ-UHFFFAOYSA-N 3exo-benzoyloxy-tropane Natural products CN1C(C2)CCC1CC2OC(=O)C1=CC=CC=C1 XQJMXPAEFMWDOZ-UHFFFAOYSA-N 0.000 description 1
- ZTVUNGGFBJEVJT-UHFFFAOYSA-N 4,4-diethylhexan-3-one Chemical compound CCC(=O)C(CC)(CC)CC ZTVUNGGFBJEVJT-UHFFFAOYSA-N 0.000 description 1
- LGJWPXGDZJETQK-UHFFFAOYSA-N 4-(2-phenylphenyl)butanoic acid Chemical compound OC(=O)CCCC1=CC=CC=C1C1=CC=CC=C1 LGJWPXGDZJETQK-UHFFFAOYSA-N 0.000 description 1
- HQFWVSGBVLEQGA-UHFFFAOYSA-N 4-aminobenzoic acid 3-(dibutylamino)propyl ester Chemical compound CCCCN(CCCC)CCCOC(=O)C1=CC=C(N)C=C1 HQFWVSGBVLEQGA-UHFFFAOYSA-N 0.000 description 1
- DHURPAIUOZIQDQ-UHFFFAOYSA-N 4-methyl-2-phenylpentanoic acid Chemical compound CC(C)CC(C(O)=O)C1=CC=CC=C1 DHURPAIUOZIQDQ-UHFFFAOYSA-N 0.000 description 1
- ORLGLBZRQYOWNA-UHFFFAOYSA-N 4-methylpyridin-2-amine Chemical compound CC1=CC=NC(N)=C1 ORLGLBZRQYOWNA-UHFFFAOYSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- TWFZGCMQGLPBSX-UHFFFAOYSA-N Carbendazim Natural products C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- UDKCHVLMFQVBAA-UHFFFAOYSA-M Choline salicylate Chemical compound C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O UDKCHVLMFQVBAA-UHFFFAOYSA-M 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- OIRAEJWYWSAQNG-UHFFFAOYSA-N Clidanac Chemical compound ClC=1C=C2C(C(=O)O)CCC2=CC=1C1CCCCC1 OIRAEJWYWSAQNG-UHFFFAOYSA-N 0.000 description 1
- FBRAWBYQGRLCEK-AVVSTMBFSA-N Clobetasone butyrate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CCC)[C@@]1(C)CC2=O FBRAWBYQGRLCEK-AVVSTMBFSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 description 1
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- PHMBVCPLDPDESM-YWIQKCBGSA-N Ecgonine Natural products C1[C@H](O)[C@@H](C(O)=O)[C@H]2CC[C@@H]1N2C PHMBVCPLDPDESM-YWIQKCBGSA-N 0.000 description 1
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 description 1
- OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 239000005867 Iprodione Substances 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- GZENKSODFLBBHQ-ILSZZQPISA-N Medrysone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 GZENKSODFLBBHQ-ILSZZQPISA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 description 1
- QQXLDOJGLXJCSE-UHFFFAOYSA-N N-methylnortropinone Natural products C1C(=O)CC2CCC1N2C QQXLDOJGLXJCSE-UHFFFAOYSA-N 0.000 description 1
- ZRXDRIHHIXLEDI-UHFFFAOYSA-N NNC(=O)C(C(=O)NN)C1=CC=CC=C1 Chemical compound NNC(=O)C(C(=O)NN)C1=CC=CC=C1 ZRXDRIHHIXLEDI-UHFFFAOYSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- RGPDEAGGEXEMMM-UHFFFAOYSA-N Nefopam Chemical compound C12=CC=CC=C2CN(C)CCOC1C1=CC=CC=C1 RGPDEAGGEXEMMM-UHFFFAOYSA-N 0.000 description 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
- ONBWJWYUHXVEJS-ZTYRTETDSA-N Normorphine Chemical compound C([C@@H](NCC1)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ONBWJWYUHXVEJS-ZTYRTETDSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- QHGUCRYDKWKLMG-MRVPVSSYSA-N Octopamine Natural products NC[C@@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-MRVPVSSYSA-N 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- MKPDWECBUAZOHP-AFYJWTTESA-N Paramethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O MKPDWECBUAZOHP-AFYJWTTESA-N 0.000 description 1
- 229920001363 Polidocanol Polymers 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- 239000005820 Prochloraz Substances 0.000 description 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
- 239000005822 Propiconazole Substances 0.000 description 1
- 239000005823 Propineb Substances 0.000 description 1
- CAJIGINSTLKQMM-UHFFFAOYSA-N Propoxycaine Chemical compound CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC CAJIGINSTLKQMM-UHFFFAOYSA-N 0.000 description 1
- QIZDQFOVGFDBKW-DHBOJHSNSA-N Pseudotropine Natural products OC1C[C@@H]2[N+](C)[C@H](C1)CC2 QIZDQFOVGFDBKW-DHBOJHSNSA-N 0.000 description 1
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- TZIZWYVVGLXXFV-FLRHRWPCSA-N Triamcinolone hexacetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@@H]2O TZIZWYVVGLXXFV-FLRHRWPCSA-N 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- RVCSYOQWLPPAOA-CVPHZBIISA-M [(5s)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate;chloride Chemical compound [Cl-].[N+]12([C@H]3CCC2CC(C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 RVCSYOQWLPPAOA-CVPHZBIISA-M 0.000 description 1
- 229960004420 aceclofenac Drugs 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 229950007008 acetaminosalol Drugs 0.000 description 1
- TWIIVLKQFJBFPW-UHFFFAOYSA-N acetaminosalol Chemical compound C1=CC(NC(=O)C)=CC=C1OC(=O)C1=CC=CC=C1O TWIIVLKQFJBFPW-UHFFFAOYSA-N 0.000 description 1
- 229960001413 acetanilide Drugs 0.000 description 1
- OGWGWBWZZQJMNO-UHFFFAOYSA-N acetic acid;5-bromo-2-hydroxybenzoic acid Chemical compound CC(O)=O.OC(=O)C1=CC(Br)=CC=C1O OGWGWBWZZQJMNO-UHFFFAOYSA-N 0.000 description 1
- 229960004582 acexamic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 229960001391 alfentanil Drugs 0.000 description 1
- 229960004663 alminoprofen Drugs 0.000 description 1
- FPHLBGOJWPEVME-UHFFFAOYSA-N alminoprofen Chemical compound OC(=O)C(C)C1=CC=C(NCC(C)=C)C=C1 FPHLBGOJWPEVME-UHFFFAOYSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-UHFFFAOYSA-N alpha-phenylglycine Chemical compound OC(=O)C(N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-UHFFFAOYSA-N 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- WEUCPZFPBXPCQU-UHFFFAOYSA-K aluminum;2-acetyloxybenzoate;dihydroxide Chemical compound O[Al+]O.CC(=O)OC1=CC=CC=C1C([O-])=O WEUCPZFPBXPCQU-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960000212 aminophenazone Drugs 0.000 description 1
- 229950011175 aminopicoline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 1
- 229940063284 ammonium salicylate Drugs 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940051880 analgesics and antipyretics pyrazolones Drugs 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- RDJGWRFTDZZXSM-RNWLQCGYSA-N benzylmorphine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCC1=CC=CC=C1 RDJGWRFTDZZXSM-RNWLQCGYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- RJTANRZEWTUVMA-UHFFFAOYSA-N boron;n-methylmethanamine Chemical compound [B].CNC RJTANRZEWTUVMA-UHFFFAOYSA-N 0.000 description 1
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 1
- 229960003655 bromfenac Drugs 0.000 description 1
- OJGDCBLYJGHCIH-UHFFFAOYSA-N bromhexine Chemical compound C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N OJGDCBLYJGHCIH-UHFFFAOYSA-N 0.000 description 1
- 229960003870 bromhexine Drugs 0.000 description 1
- MOYGZHXDRJNJEP-UHFFFAOYSA-N buclizine Chemical compound C1=CC(C(C)(C)C)=CC=C1CN1CCN(C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1 MOYGZHXDRJNJEP-UHFFFAOYSA-N 0.000 description 1
- 229960001705 buclizine Drugs 0.000 description 1
- IJTPQQVCKPZIMV-UHFFFAOYSA-N bucloxic acid Chemical compound ClC1=CC(C(=O)CCC(=O)O)=CC=C1C1CCCCC1 IJTPQQVCKPZIMV-UHFFFAOYSA-N 0.000 description 1
- 229950005608 bucloxic acid Drugs 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 229960003369 butacaine Drugs 0.000 description 1
- 229960000400 butamben Drugs 0.000 description 1
- IUWVALYLNVXWKX-UHFFFAOYSA-N butamben Chemical compound CCCCOC(=O)C1=CC=C(N)C=C1 IUWVALYLNVXWKX-UHFFFAOYSA-N 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- JNPZQRQPIHJYNM-UHFFFAOYSA-N carbendazim Chemical compound C1=C[CH]C2=NC(NC(=O)OC)=NC2=C1 JNPZQRQPIHJYNM-UHFFFAOYSA-N 0.000 description 1
- 239000006013 carbendazim Substances 0.000 description 1
- MSPRUJDUTKRMLM-UHFFFAOYSA-N caroverine Chemical compound O=C1N(CCN(CC)CC)C2=CC=CC=C2N=C1CC1=CC=C(OC)C=C1 MSPRUJDUTKRMLM-UHFFFAOYSA-N 0.000 description 1
- 229960003355 caroverine Drugs 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960002798 cetrimide Drugs 0.000 description 1
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002688 choline salicylate Drugs 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 description 1
- 229950010886 clidanac Drugs 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 229960001146 clobetasone Drugs 0.000 description 1
- 229960004299 clocortolone Drugs 0.000 description 1
- YMTMADLUXIRMGX-RFPWEZLHSA-N clocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O YMTMADLUXIRMGX-RFPWEZLHSA-N 0.000 description 1
- DGMZLCLHHVYDIS-UHFFFAOYSA-N clometacin Chemical compound CC=1N(CC(O)=O)C2=CC(OC)=CC=C2C=1C(=O)C1=CC=C(Cl)C=C1 DGMZLCLHHVYDIS-UHFFFAOYSA-N 0.000 description 1
- 229950001647 clometacin Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 229960004415 codeine phosphate Drugs 0.000 description 1
- 229960003871 codeine sulfate Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- PHMBVCPLDPDESM-UHFFFAOYSA-N d-Pseudoekgonin Natural products C1C(O)C(C(O)=O)C2CCC1N2C PHMBVCPLDPDESM-UHFFFAOYSA-N 0.000 description 1
- 229960001145 deflazacort Drugs 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- 229950003851 desomorphine Drugs 0.000 description 1
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 description 1
- 229960002593 desoximetasone Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- 229960000605 dexrazoxane Drugs 0.000 description 1
- WDEFBBTXULIOBB-WBVHZDCISA-N dextilidine Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C WDEFBBTXULIOBB-WBVHZDCISA-N 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- 229960003461 dezocine Drugs 0.000 description 1
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 229960004875 difluprednate Drugs 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 229950004655 dimepheptanol Drugs 0.000 description 1
- QIRAYNIFEOXSPW-UHFFFAOYSA-N dimepheptanol Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(O)CC)C1=CC=CC=C1 QIRAYNIFEOXSPW-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 description 1
- 229960000385 dyclonine Drugs 0.000 description 1
- PHMBVCPLDPDESM-FKSUSPILSA-N ecgonine Chemical compound C1[C@H](O)[C@H](C(O)=O)[C@H]2CC[C@@H]1N2C PHMBVCPLDPDESM-FKSUSPILSA-N 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 229950010996 enfenamic acid Drugs 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- JYRBQCWXZNDERM-XIRDDKMYSA-N etazocine Chemical compound C1C2=CC=C(O)C=C2[C@]2(CC)[C@@H](CC)[C@H]1N(C)CC2 JYRBQCWXZNDERM-XIRDDKMYSA-N 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 229960004578 ethylmorphine Drugs 0.000 description 1
- 229960001493 etofenamate Drugs 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229950003537 fenclorac Drugs 0.000 description 1
- UBAJTZKNDCEGKL-UHFFFAOYSA-N fenoverine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1C(=O)CN1CCN(CC=2C=C3OCOC3=CC=2)CC1 UBAJTZKNDCEGKL-UHFFFAOYSA-N 0.000 description 1
- 229960001966 fenoverine Drugs 0.000 description 1
- JXJPYHDHJZJWRI-UHFFFAOYSA-N fenpiprane Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCN1CCCCC1 JXJPYHDHJZJWRI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229920005570 flexible polymer Polymers 0.000 description 1
- 229960003469 flumetasone Drugs 0.000 description 1
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 229960001048 fluorometholone Drugs 0.000 description 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
- 229960003667 flupirtine Drugs 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- GWOFUCIGLDBNKM-UHFFFAOYSA-N glafenine Chemical compound OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=CC(Cl)=CC=C12 GWOFUCIGLDBNKM-UHFFFAOYSA-N 0.000 description 1
- 229960001650 glafenine Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 229960002383 halcinonide Drugs 0.000 description 1
- 229940115747 halobetasol Drugs 0.000 description 1
- 229960002475 halometasone Drugs 0.000 description 1
- GGXMRPUKBWXVHE-MIHLVHIWSA-N halometasone Chemical compound C1([C@@H](F)C2)=CC(=O)C(Cl)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O GGXMRPUKBWXVHE-MIHLVHIWSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960003698 hexylcaine hydrochloride Drugs 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229950009183 ibufenac Drugs 0.000 description 1
- CYWFCPPBTWOZSF-UHFFFAOYSA-N ibufenac Chemical compound CC(C)CC1=CC=C(CC(O)=O)C=C1 CYWFCPPBTWOZSF-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- RONFGUROBZGJKP-UHFFFAOYSA-N iminoctadine Chemical compound NC(N)=NCCCCCCCCNCCCCCCCCN=C(N)N RONFGUROBZGJKP-UHFFFAOYSA-N 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- ONUFESLQCSAYKA-UHFFFAOYSA-N iprodione Chemical compound O=C1N(C(=O)NC(C)C)CC(=O)N1C1=CC(Cl)=CC(Cl)=C1 ONUFESLQCSAYKA-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- QFGMXJOBTNZHEL-UHFFFAOYSA-N isoxepac Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(CC(=O)O)=CC=C21 QFGMXJOBTNZHEL-UHFFFAOYSA-N 0.000 description 1
- 229950011455 isoxepac Drugs 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- IMYHGORQCPYVBZ-NLFFAJNJSA-N lofentanil Chemical compound CCC(=O)N([C@@]1([C@@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 IMYHGORQCPYVBZ-NLFFAJNJSA-N 0.000 description 1
- 229950010274 lofentanil Drugs 0.000 description 1
- RBLKLJDYAHZCFW-UHFFFAOYSA-L magnesium;2-acetyloxybenzoate Chemical compound [Mg+2].CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O RBLKLJDYAHZCFW-UHFFFAOYSA-L 0.000 description 1
- 229960003577 mebeverine Drugs 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960001011 medrysone Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 description 1
- 229960000365 meptazinol Drugs 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- YGSVZRIZCHZUHB-COLVAYQJSA-N metazocine Chemical compound C1C2=CC=C(O)C=C2[C@]2(C)CCN(C)[C@@]1([H])[C@@H]2C YGSVZRIZCHZUHB-COLVAYQJSA-N 0.000 description 1
- 229950009131 metazocine Drugs 0.000 description 1
- 229960005189 methadone hydrochloride Drugs 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- ZPUCINDJVBIVPJ-XGUBFFRZSA-N methyl (1s,3s,4s,5r)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-XGUBFFRZSA-N 0.000 description 1
- ABJKIHHNDMEBNA-UHFFFAOYSA-N methylchromone Chemical compound C1=CC=C2C(=O)C(C)=COC2=C1 ABJKIHHNDMEBNA-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- OJGQFYYLKNCIJD-UHFFFAOYSA-N miroprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CN(C=CC=C2)C2=N1 OJGQFYYLKNCIJD-UHFFFAOYSA-N 0.000 description 1
- 229950006616 miroprofen Drugs 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- VSEAAEQOQBMPQF-UHFFFAOYSA-N morpholin-3-one Chemical compound O=C1COCCN1 VSEAAEQOQBMPQF-UHFFFAOYSA-N 0.000 description 1
- 229960002186 morpholine salicylate Drugs 0.000 description 1
- MYCMTMIGRXJNSO-UHFFFAOYSA-N moxaverine Chemical compound N=1C(CC)=CC2=CC(OC)=C(OC)C=C2C=1CC1=CC=CC=C1 MYCMTMIGRXJNSO-UHFFFAOYSA-N 0.000 description 1
- 229960002902 moxaverine Drugs 0.000 description 1
- MSLICLMCQYQNPK-UHFFFAOYSA-N n-(4-bromophenyl)acetamide Chemical compound CC(=O)NC1=CC=C(Br)C=C1 MSLICLMCQYQNPK-UHFFFAOYSA-N 0.000 description 1
- LKPFBGKZCCBZDK-UHFFFAOYSA-N n-hydroxypiperidine Chemical compound ON1CCCCC1 LKPFBGKZCCBZDK-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- CVRCFLFEGNKMEC-UHFFFAOYSA-N naphthalen-1-yl 2-hydroxybenzoate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC2=CC=CC=C12 CVRCFLFEGNKMEC-UHFFFAOYSA-N 0.000 description 1
- 229960000751 nefopam Drugs 0.000 description 1
- KRGPXXHMOXVMMM-UHFFFAOYSA-N nicotianamine Natural products OC(=O)C(N)CCNC(C(O)=O)CCN1CCC1C(O)=O KRGPXXHMOXVMMM-UHFFFAOYSA-N 0.000 description 1
- 229960000916 niflumic acid Drugs 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 229960001907 nitrofurazone Drugs 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229960004013 normethadone Drugs 0.000 description 1
- WCJFBSYALHQBSK-UHFFFAOYSA-N normethadone Chemical compound C=1C=CC=CC=1C(CCN(C)C)(C(=O)CC)C1=CC=CC=C1 WCJFBSYALHQBSK-UHFFFAOYSA-N 0.000 description 1
- 229950006134 normorphine Drugs 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960001576 octopamine Drugs 0.000 description 1
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
- 229960004110 olsalazine Drugs 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 229960005113 oxaceprol Drugs 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 229960002016 oxybutynin chloride Drugs 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 229930015582 oxymatrine Natural products 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 229960002858 paramethasone Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- DGBWPZSGHAXYGK-UHFFFAOYSA-N perinone Chemical compound C12=NC3=CC=CC=C3N2C(=O)C2=CC=C3C4=C2C1=CC=C4C(=O)N1C2=CC=CC=C2N=C13 DGBWPZSGHAXYGK-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- QXDAEKSDNVPFJG-UHFFFAOYSA-N phenacaine Chemical compound C1=CC(OCC)=CC=C1N\C(C)=N\C1=CC=C(OCC)C=C1 QXDAEKSDNVPFJG-UHFFFAOYSA-N 0.000 description 1
- 229950007049 phenacaine Drugs 0.000 description 1
- 229960003799 phenazopyridine hydrochloride Drugs 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- OIQJEQLSYJSNDS-UHFFFAOYSA-N piroctone Chemical compound CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O OIQJEQLSYJSNDS-UHFFFAOYSA-N 0.000 description 1
- 229950001046 piroctone Drugs 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
- 229960002226 polidocanol Drugs 0.000 description 1
- 229960001896 pramocaine Drugs 0.000 description 1
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- BOFKYYWJAOZDPB-FZNHGJLXSA-N prednival Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O BOFKYYWJAOZDPB-FZNHGJLXSA-N 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- TVLSRXXIMLFWEO-UHFFFAOYSA-N prochloraz Chemical compound C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl TVLSRXXIMLFWEO-UHFFFAOYSA-N 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 229960003192 propacetamol Drugs 0.000 description 1
- QTGAJCQTLIRCFL-UHFFFAOYSA-N propacetamol Chemical compound CCN(CC)CC(=O)OC1=CC=C(NC(C)=O)C=C1 QTGAJCQTLIRCFL-UHFFFAOYSA-N 0.000 description 1
- 229960003981 proparacaine Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- STJLVHWMYQXCPB-UHFFFAOYSA-N propiconazole Chemical compound O1C(CCC)COC1(C=1C(=CC(Cl)=CC=1)Cl)CN1N=CN=C1 STJLVHWMYQXCPB-UHFFFAOYSA-N 0.000 description 1
- KKMLIVYBGSAJPM-UHFFFAOYSA-L propineb Chemical compound [Zn+2].[S-]C(=S)NC(C)CNC([S-])=S KKMLIVYBGSAJPM-UHFFFAOYSA-L 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- ZBAFFZBKCMWUHM-UHFFFAOYSA-N propiram Chemical compound C=1C=CC=NC=1N(C(=O)CC)C(C)CN1CCCCC1 ZBAFFZBKCMWUHM-UHFFFAOYSA-N 0.000 description 1
- 229950003779 propiram Drugs 0.000 description 1
- 229950003255 propoxycaine Drugs 0.000 description 1
- 229960002466 proquazone Drugs 0.000 description 1
- JTIGKVIOEQASGT-UHFFFAOYSA-N proquazone Chemical compound N=1C(=O)N(C(C)C)C2=CC(C)=CC=C2C=1C1=CC=CC=C1 JTIGKVIOEQASGT-UHFFFAOYSA-N 0.000 description 1
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 229960002991 quinine salicylate Drugs 0.000 description 1
- 229960003394 remifentanil Drugs 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 229960001549 ropivacaine Drugs 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 239000012781 shape memory material Substances 0.000 description 1
- 150000003378 silver Chemical class 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002494 tetracaine hydrochloride Drugs 0.000 description 1
- 229960004412 thebacon Drugs 0.000 description 1
- RRJQTGHQFYTZOW-ILWKUFEGSA-N thebacon Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C=C(OC(C)=O)[C@@H]1OC1=C2C3=CC=C1OC RRJQTGHQFYTZOW-ILWKUFEGSA-N 0.000 description 1
- 229960001312 tiaprofenic acid Drugs 0.000 description 1
- 229960001402 tilidine Drugs 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- APEJMQOBVMLION-VOTSOKGWSA-N trans-cinnamamide Chemical compound NC(=O)\C=C\C1=CC=CC=C1 APEJMQOBVMLION-VOTSOKGWSA-N 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960004221 triamcinolone hexacetonide Drugs 0.000 description 1
- 229960005345 trimebutine Drugs 0.000 description 1
- FYZXEMANQYHCFX-UHFFFAOYSA-K tripotassium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [K+].[K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O FYZXEMANQYHCFX-UHFFFAOYSA-K 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- CYHOMWAPJJPNMW-JIGDXULJSA-N tropine Chemical compound C1[C@@H](O)C[C@H]2CC[C@@H]1N2C CYHOMWAPJJPNMW-JIGDXULJSA-N 0.000 description 1
- 229960001530 trospium chloride Drugs 0.000 description 1
- LEHFPXVYPMWYQD-XHIJKXOTSA-N ulobetasol Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]2(C)C[C@@H]1O LEHFPXVYPMWYQD-XHIJKXOTSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 229930189508 virginol Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/3205—Excision instruments
- A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
- A61B17/320725—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions with radially expandable cutting or abrading elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/3205—Excision instruments
- A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B17/22004—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves
- A61B17/22012—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves in direct contact with, or very close to, the obstruction or concrement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/09—Guide wires
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1018—Balloon inflating or inflation-control devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/104—Balloon catheters used for angioplasty
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00477—Coupling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00743—Type of operation; Specification of treatment sites
- A61B2017/00778—Operations on blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B17/22004—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves
- A61B17/22012—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves in direct contact with, or very close to, the obstruction or concrement
- A61B2017/22014—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves in direct contact with, or very close to, the obstruction or concrement the ultrasound transducer being outside patient's body; with an ultrasound transmission member; with a wave guide; with a vibrated guide wire
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B2017/22051—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for with an inflatable part, e.g. balloon, for positioning, blocking, or immobilisation
- A61B2017/22061—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for with an inflatable part, e.g. balloon, for positioning, blocking, or immobilisation for spreading elements apart
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1086—Balloon catheters with special features or adapted for special applications having a special balloon surface topography, e.g. pores, protuberances, spikes or grooves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1093—Balloon catheters with special features or adapted for special applications having particular tip characteristics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Mechanical Engineering (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Surgical Instruments (AREA)
- Finger-Pressure Massage (AREA)
Abstract
本申请公开了一种刻划球囊导管,包括:轴;可膨胀的球囊,所述可膨胀的球囊安装在轴的远侧区域处;膨胀管腔;导丝管腔,所述导丝管腔布置在轴的内部;手柄,所述手柄安装在轴的近端处,所述手柄具有导丝端口和球囊膨胀端口;弹簧,所述弹簧在手柄的远端处同轴地安装在所述轴的内部,所述弹簧具有远侧区域;至少两个刻划线管腔,所述刻划线管腔在轴的内部彼此靠近地设置在轴的一侧,靠近导丝管腔,所述刻划线管腔具有在球囊的近侧开始的远端和在弹簧的远侧结束的近端;至少两个刻划线,每个刻划线都在一个刻划线管腔内,所述刻划线具有:安装在轴上且位于轴的远端和球囊之间的端部;中间部分;近侧部分;以及固定在弹簧上的近端。
Description
本分案申请是基于申请号为201680069881X(其国际申请号为PCT/US2016/059537)、申请日为2016年10月28日、发明名称为“具有平移刻划线的刻划球囊”的中国专利申请的分案申请。
背景技术
球囊扩张导管用于治疗血管中的病变部。然而,在导航曲折解剖结构和安全穿过非常紧的病变部时遇到困难。而且,一些病变部很难只使用球囊来扩张,需要集中力量来在安全的膨胀压力下扩张病变部。
Solar等的美国专利No.6394995介绍了用于提供增大的力来治疗病变的系统。该系统有柔性推进部件,该柔性推进部件有:追踪部件,该追踪部件可在导丝上滑动;以及球囊,该球囊有附接在追踪部件上的远端。但是这种类型的系统提供了有限的集中力,并缺乏可推动性和可操作性。
发明内容
根据本公开的一个方面,提供了一种刻划球囊导管。导管允许刻划线平移(例如纵向),结合球囊由于充气而膨胀。这能够有利地允许线运动至正确的位置,用于刻划病变部,但是当不希望用于该目的时退回(例如,当球囊未膨胀,并追踪至治疗部位时)。而且,它允许根据球囊膨胀水平来使得刻划线延伸正确的量。在一个特殊实施例中,本发明提供了能够用于治疗脉管病变部的刻划球囊导管。在使用中,球囊将刻划线压入病变部位。导管包括:轴;可膨胀球囊,该可膨胀球囊安装在轴的远侧部分上;在球囊近侧与轴相连的部件或弹簧;以及至少一个刻划线。在一些实施例中,刻划线有在轴的远端和球囊之间安装在该轴上的固定端。刻划线有与该部件或弹簧相连的可纵向运动端部以及布置在球囊外部的中间部分。
在一些实施例中,可运动的刻划线端部是线的近端。这些端部延伸至部件的管腔中。在一些实施例中,部件包括纵向弹性部件例如弹性聚合物或橡胶或弹簧,或与该纵向弹性部件相互作用。在一些实施例中,装置还包括第二部件,弹簧位于部件和第二部件之间。
在一些实施例中,该装置包括在轴的内部或外部的刻划线管腔。该刻划线管腔包含一个或多个刻划线。在一些实施例中,装置包括在轴内部的两个管腔和在该管腔内部的两个刻划线。
在其它实施例中,刻划球囊导管使用偏压部件,例如安装在手柄组件的毂形部内的弹簧。轴穿过该弹簧,并延伸至手柄组件中。毂形部盖布置在轴上和毂形部上。在一些实例下,毂形部盖减轻毂形部弹簧连接的应力。刻划线焊接或以其它方式附接在弹簧上。
附图说明
通过参考下面结合附图的说明,可以更好地理解本发明的上述和其它优点,附图中:
图1a是本发明装置的实例的正视图。
图1b是图1a的指示部分的放大图。
图1c是图1a的指示部分的放大图。
图2a是本发明装置的另一实例的正视图。
图2b是图2a的指示部分的放大图。
图2c是图2a的指示部分的放大图。
图3a是本发明装置的另一实例的正视图。
图3b是图3a的指示部分的放大图。
图3c是图3a的指示部分的放大图。
图4a是本发明装置的另一实例的正视图。
图4b是图4a的指示部分的放大图。
图4c是图4a的指示部分的放大图。
图5a是本发明装置的另一实例的正视图。
图5b是图5a的指示部分的放大图。
图5c是图5a的指示部分的放大图。
图6是本发明装置的另一实施例的正视图。
图7a是表示图1的实施例在剖面BB处的端视图。
图7b类似于图7a,表示在不同的本发明实施例中的剖面AA。
图8a是表示装置的实施例沿与剖面AA类似的剖面的剖视图。
图8b类似于图8a,表示在不同的本发明实施例中的剖面AA。
图9是图6的装置的横剖图。
附图并不必须成正比或按比例绘制。例如,为了清楚,一些元件的尺寸可能相对于其它元件进行夸大,或者多个物理部件可以包含在一个功能块或元件中。而且,参考标号有时可以在附图中重复,以便表示相应或类似的元件。而且,附图中表示的一些块可以组合成单个功能。
具体实施方式
在下面的详细说明中阐述了许多具体细节,以便提供对本发明的透彻理解。本领域普通技术人员应当知道,可以在没有这些具体细节的情况下实践本发明。在其它情况下,公知的方法、过程、部件或结构可以并不详细说明,以免模糊本发明。
本发明涉及用于治疗血管的系统和方法。本发明的系统和方法的原理和操作可以参考附图和相应说明而更好地理解。
本发明的应用并不局限于在下面的说明书中所述或在附图中所示的部件的结构和布置的细节。本发明能够有其它实施例或者以多种方式来实践或执行。还有,应当理解,这里使用的措辞和术语是为了说明目的,而不应当认为是限制。
为了清楚,在单独实施例中所述的本发明的特定特征也可以在单个实施例中组合地提供。相反,为了简明,在单个实施例中所述的本发明的多个特征也可以单独提供或以任何合适的子组合来提供。
部件表
定义
“固定”-在装置的操作环境内不可分离。
“操作环境”-装置可设想地操作为血管内球囊导管的任何环境。
“纵向弹性”-纵向反复运动的能力。
“机械连通的定义”-介绍一个物体充分连接(从而它的运动使得另一物体运动,反之亦然)的能力。
“导轨”-基本纵向物体,该物体支承和引导另一物体的运动。
“可滑动地接合”部件是装配至通道中或环绕导轨的部件,以使得部件大致或基本在二维中受到限制。不是三维限制部件,该部件在一定程度上不受限制,从而允许部件在通道内或沿导轨纵向运动相当大的距离。当系统有限制纵向运动但仍然允许较大纵向运动的止动件或其它部件时,认为该部件可滑动地接合。
“有效接合”-当划痕线足够好地(对于治疗)与病变部接合(以便明显影响病变部)时,该划痕线有效接合。
本发明的导管能够是在线上、较短的快速交换或快速交换平台。当导管是较短的快速交换平台时,内部部件可以横过导管的整个长度。
转到本发明的实施例,图1a描述了本发明装置的实施例。在本发明的实施例中,刻划球囊(SCB)导管100在正视图中表示,其中,选定部分以放大图表示。SCB导管100包括以下部件。例如,导管100包括轴105。该轴105有与轴中间部分107连接的轴近侧部分106和与轴远侧部分108连接的轴中间部分107。轴锥形部分111使得轴近侧部分106与轴中间部分107连接。轴105还包括轴壁109,该轴壁109为轴105提供一定程度的刚性,以使得轴105适合(如本领域普通技术人员所判断)追踪至既不太刚性也不太柔性的脉管系统或曲折脉管系统中。在一些实施例中,通过向SCB导管100添加纵向部件(未示出)而改变刚性或柔性。在一些实施例中,轴105包括Pebax。
在一些实施例中,轴锥形部分111固定在轴中间部分107上。在一些实施例中,轴壁109在轴远端110结束之前结束。
为了本文目的,轴远端110是轴105的、首先进入患者体内的端部。类似地,任何其它“远侧”特征部件的意思是比任何其它部件部分更靠近轴远端110的部件部分。类似地,任何“近侧”特征部件的意思是比任何其它部件部分更远离轴远端110的部件部分。
SCB导管100还包括可膨胀球囊(IB)115。可膨胀球囊115安装在轴105上并在轴远侧部分108内。在一些实施例中,可膨胀球囊115在轴远端110处结束。在这些或其它实施例中,可膨胀球囊115固定在轴105上。
可膨胀球囊115包括1B近端130和1B远端131。典型实施例具有用作可膨胀球囊115的柔性聚合物薄膜。在可膨胀球囊115安装至轴105上之后,IB外表面132面向管腔地结束。对于本发明,1B近端130是使得可膨胀球囊115的近端附接或固定在轴105上的可膨胀球囊115部分。1B近端130确定为可膨胀球囊115的近侧部分,该近侧部分在可膨胀球囊115膨胀后保持与轴105接触。
对于本发明,IB远端131是使得可膨胀球囊115在远侧附接或固定在轴105上的可膨胀球囊115部分。IB远端131确定为可膨胀球囊115的远侧部分,该远侧部分在可膨胀球囊115膨胀后保持与轴105接触。
IB管腔133与可膨胀球囊115流体连通,这使得可膨胀球囊115能够通过经过IB管腔133的流体而膨胀。
SCB导管100还包括导丝管腔(GWL)119,该导丝管腔119至少从轴近端112纵向延伸至超过轴远端110。GW管腔119结束于GWL远端120处。
在一些实施例中,IB近端130和IB远端131使用本领域普通技术人员已知的任何方法而与GWL外表面121或轴105连接。
SCB导管100还包括刻划线(SCW)135。刻划线135包括固定SCW端部136、SCW IB部分137和可运动SCW端部138。固定SCW端部136在IB远端131的远侧连接在轴远侧部分108内。在一些实施例中,固定SCW端部136附接在GWL外表面121上。在其它实施例中,固定SCW端部136附接在轴壁109的外侧上。固定SCW端部136使用本领域普通技术人员已知的任何方法来附接。
这种结构提供了在可膨胀球囊115旁边的集中力元件(刻划线135)。
在刻划线135和IB外表面132之间的距离能够是本领域普通技术人员认为有利的任何值。一旦经过可膨胀球囊115,刻划线135就潜入轴壁109下面,从而在轴105的内部向近侧延伸。可运动SCW端部138布置在轴105内部并在轴近侧部分106内。在一些实施例中,刻划线135占据SCW管腔1139的至少一部分(如图8a和8b中所示)。
图1a-图5b表示了SCB导管100具有两个刻划线。在一些实施例中,SCB导管100具有1-15、3-10或2-5个刻划线。在一些实施例中,SCW 135的直径在0.003英寸和0.040英寸之间,或者在0.005英寸和0.015英寸之间、在0.008英寸和0.012英寸之间。在一些实施例中,SCW 135为0.10英寸。SCW 135不需要有均匀的直径。在一些实施例中,SCW远侧部分1351的直径大于SCW近侧部分1352的直径。在一些实施例中,SCW远侧部分1351的直径小于SCW近侧部分1352的直径。在一些实施例中,SCW135包括金属、金属合金、聚合物以及基于金属或聚合物的形状记忆材料。
SCB导管100还包括毂形部140。该毂形部140位于轴105的内部并在轴近侧部分106内。毂形部140包括用于导丝管腔119穿过的GWL通道141。毂形部140还包括与可运动SCW端部138相互作用的一个或多个毂形部管腔145。
在一些实施例中,相互作用包括可运动SCW端部138连接至毂形部管腔145中或连接至毂形部管腔145上。在一些实施例中,可运动SCW端部138固定在毂形部管腔145上。在其它实施例中,相互作用包括可运动SCW端部138滑动接合至毂形部管腔145内部。在一些实施例中,毂形部140包括任何可生物相容材料,例如金属、金属合金和聚合物。在一些实施例中,毂形部140包括尼龙、Pebax或本领域普通技术人员已知的任何其它合适材料。
在一些实施例中,毂形部140基本上固定在轴近侧部分106内部,其中,可运动SCW端部138滑动接合或布置在毂形部管腔145内。在一些实施例中,毂形部140可纵向运动或有弹性,从而使得可运动SCW端部138能够通过向远侧拉动毂形部140、通过使毂形部140运动或通过拉伸毂形部140的材料而纵向运动。例如,在一些实施例中,毂形部140有弹性。当可运动SCW端部138受到指向远侧的力(该力使它向远侧运动)时以及当可运动SCW端部138固定在毂形部管腔145上或毂形部管腔145内时,该运动将拉伸毂形部140。恢复力或者与向远侧拉伸相反的力(反作用力)将在指向远侧的力移除时使得可运动SCW端部138基本返回就位。
在一些实施例中,毂形部140由弹簧200偏压。在一些实施例中,弹簧200安装在毂形部140的远侧,且在一些实施例中,弹簧200安装在毂形部140的近侧。
SCW导管100还包括手柄组件150。该手柄组件150与轴近端109相连。手柄组件150包括HA端口子组件和HA过渡子组件。HA端口子组件占据手柄组件150的近端的至少一部分。且HA过渡子组件占据手柄组件150的远端的至少一部分。HA端口子组件与HA过渡子组件相关。在一些实施例中,HA端口子组件与HA过渡子组件连接或者固定在HA过渡子组件上。在一些实施例中,HA端口子组件和HA过渡子组件一起形成单件物体或多个物体,或者形成由包含SCW导管100的纵向轴线的平面分开的单件物体。
HA过渡子组件包括HA逐步降低部分156,该HA逐步降低部分156布置在HA过渡子组件的远端处。在一些实施例中,HA过渡子组件的远端和手柄组件150的远端是同一物体。
HA逐步降低部分156是HA过渡子组件的一部分,其中,总体外部尺寸有减小至较小直径的阶梯过渡,它的尺寸设置成与轴近端112接合。
在一些实施例中,过渡子组件152没有HA逐步降低部分156。
轴105通过轴近端112和HA逐步降低部分156而与手柄组件150相关。在一些实施例中,轴105与手柄组件150连接。例如,轴近端112能够滑过HA逐步降低部分156,且该部件能够固定,例如通过焊接、熔合、胶接等。或者,在轴近端112和HA过渡子组件之间的摩擦配合能够足够强,以便将部件固定在一起。在没有HA逐步降低部分156的一些实施例中,轴近端112能够通过在轴近端112和HA过渡子组件152之间的对接接头而与手柄组件150连接。
HA端口子组件包括HA GW端口154,该HA GW端口154占据HA端口子组件的近端。在一些形式的手柄组件150中,HA GW端口154指向远离轴远端110。HA GW端口154允许从SCB导管100的外部进入导丝管腔119、在一些形式的手柄组件150中,HA端口子组件还包括HA 1B管腔端口153,该HA 1B管腔端口153从SCB导管100的纵向轴线以本领域普通技术人员认为有利的任意角度倾斜伸出。在一些形式中,HA 1B管腔端口153流入导丝端口导丝管腔区域,在其它实施例中,流向在导丝管腔119内部或外部(未示出)的单独管腔。HA 1B管腔端口153还允许从在SCB导管100外部进入通道(导丝管腔119或IB管腔133(IBL)),该通道将气体或充胀流体运送至可膨胀球囊115中,以便使它膨胀,或者将气体或膨胀流体从可膨胀球囊115送出,以便使它缩小。
操作上,在由图1a实施例教导的装置中,例如为了治疗钙化病变,医师切开患者的组织,直到露出合适尺寸的血管。血管必须沿通路通向病变部位,SCB导管100能够沿该通路运动。在一些实施例中,病变部位的位置使得本领域普通技术人员选择多多少少柔性的轴105或SCB导管100。
医师打开血管,将导丝插入血管中,并在超声波、磁共振、荧光镜或一些其它类型的引导下使得导丝前进穿过患者的脉管系统。一旦医师将导丝布置在令人满意的部位,医师就使得导丝的近端穿入GWL远端120,穿过导丝管腔119,并最终通过HA GW端口154而离开SCB导管100。在导丝就位和安装在SCB导管100中的情况下,医师沿导丝操纵SCB导管100,直到可膨胀球囊115到达病变部位附近的合适位置。通常,该位置将使得至少一个刻划线135与病变部有效接合。然后,医师使得可膨胀球囊115膨胀,直到刻划线135牢固地压入病变部或使得该病变部破裂。一旦完成通过SCB导管100的病变治疗,医师就使得可膨胀球囊115缩小,这使得刻划线135松弛离开病变部和血管壁。
只要可膨胀球囊115保持膨胀,刻划线135就接触病变部。膨胀时间对应于医师选择用于使得刻划线135接触病变部的时间。本领域普通技术人员使用5秒至5分钟的膨胀时间。本领域普通技术人员根据病变部的性质来确定合适的膨胀时间和膨胀速度。
本发明的一个方面包括刻划线135在球囊膨胀过程中的性能,特别是,包括可运动SCW端部138的性能。
当可膨胀球囊115膨胀时,刻划线(一个或多个)135向外扩张,从而使得该刻划线135处于纵向拉伸。由该纵向拉伸引起的力矢量的分量从固定SCW端部136指向近侧和从可运动SCW端部138指向远侧。但是固定SCW端部136固定在轴105或GWL外表面121上。因此,刻划线135的任何运动将在可运动SCW端部138处发生。毂形部140限制可运动SCW端部138的运动,从而允许它纵向运动。这种运动减少了可膨胀球囊115上的应变,从而帮助保持它的工程设计形状和帮助避免在球囊网中发生任何扭结,该扭结有时在现有技术装置中可见,该现有技术装置有在两端基本固定的刻划线。
当医师使得球囊缩小时,先前使得刻划线135膨胀的力消失,从而使得刻划线135(和可运动SCW端部138)能够松弛。毂形部140限制可运动SCW端部138的松弛。具体地说,毂形部140将可运动SCW端部138引导成与球囊膨胀前的可运动SCW端部138的初始布置类似的布置。毂形部140的作用将帮助调节膨胀和缩小的步骤,从而提高它们的可预测性。
回到图1a,图1a描述了如上所述的导管。特殊轴105能够通过本领域普通技术人员已知的多种方法来制造。图1a中所示的实施例包括轴105,该轴105通过HA远端部分155和HA逐步降低部分156而与手柄组件150相连(附接、连接、结合)。HA逐步降低部分156占据轴管腔113,并使得轴近端112与大气基本密封。在一些实施例中,轴近端112和HA远端部分155通过粘接剂而胶接在一起。在其它实施例中,不使用粘接剂。本领域普通技术人员知道其它连接方法。这些认为是在本发明的范围内。
在图1a中,HA逐步降低部分156沿着HA远端部分155的长度位于中间。而且,在该实施例中,HA远端部分155还用作毂形部140。参考标号表示相同的部件,因为该部件既用作HA远端155,也用作毂形部140。
图1b是轴近侧部分106的放大图。轴105在轴近端112处结束,并接收毂形部140,该毂形部140是或不是HA远端155的一部分。毂形部140能够有一个或多个毂形部管腔145--图1b表示了两个毂形部管腔145。在该实施例中,这些毂形部管腔145纵向伸入毂形部140中。但是,SCB导管100不需要纵向毂形部管腔145来正确地起作用。毂形部管腔145只需要用于可滑动和可逆地接收可运动SCW端部138。图1b表示了毂形部管腔145伸入毂形部140内大约四分之三的毂形部140长度,但这不重要。在一些实施例中,毂形部管腔145完全延伸穿过毂形部140。毂形部管腔145伸入毂形部140中与可运动SCW端部138伸入毂形部管腔145内一样远或者更远。图1b还表示了刻划线135和可运动SCW端部138。在该实施例,刻划线135在向近侧离开SCW管腔1139之后向外逐渐变小或张开。可运动SCW端部138占据毂形部管腔145的一部分。在该实施例中,SCB导管100包括每个可运动SCW端部138一个毂形部管腔145。但是存在其它实施例,其中,毂形部管腔能够与一个以上的可运动SCW端部138相互作用。
最后,图1b表示了导丝管腔119穿过毂形部140和继续进入轴105内。图1c描绘了刻划线135向远侧离开SCW管腔1139的区域的放大视图。
刻划线135具有穿过SCB导管100一部分的通路。SCW管腔1139是沿一些或全部轴中间部分107接收刻划线135的管腔。我们将在SCW管腔1139内的刻划线135部分称为SCW管腔部分1361。我们将膨胀球囊115附近的刻划线135部分称为SCW IB部分137。
为了介绍目的,我们在可运动SCW端部138处开始该通路。可运动SCW端部138位于毂形部管腔145内。当我们沿刻划线135向远侧运动时,我们到达SCW管腔1139的近端,刻划线135占据该SCW管腔1139。在一些实施例中,刻划线135在SCW管腔1139的近侧向内逐渐变细。刻划线135在管腔的远端处向远侧离开SCW管腔1139。我们将刻划线135的、在该出口处开始的部分称为SCW IB部分137。在离开后,刻划线135在向远侧前进时向外张开,从而沿基本纵向方向延伸,直到线经过IB远端131。在该点处,刻划线135转向内,直到它到达轴远侧部分108或GWL外表面121。固定SCW端部136在可膨胀球囊115的远侧或者在IB远端131附接至SCB导管100上的点处或附近附接在SCB导管100上。在SCW IB部分137内的刻划线135的部分具有沿着可膨胀球囊115的纵向区域。该纵向部分从SCB导管100的中心轴线伸出的距离(线距离)能够有多个值。当可膨胀球囊115膨胀时IB外表面132从中心轴线伸出的距离是球囊膨胀距离。通常,(线距离)/(球囊膨胀距离)在以下范围内:0.99-1.01;0.90-1.1;0.8-1.2;和0.5-1.5。
在由图1a的装置表示的一组实施例的操作中,医师如上所述布置可膨胀球囊115。医师通过HA 1B管腔端口153而使得可膨胀球囊115膨胀。球囊膨胀首先在刻划线135上施加向外的压力,然后施加在病变部上。在不希望受到任何特殊操作原理的限制的情况下,我们相信,因为可运动SCW端部138可运动地连接,所以刻划线135不会促成由膨胀或过度膨胀而引起的球囊变形。因为线能够向外运动,因此它不会明显地罩住球囊。罩住效果将防止球囊膨胀超过该线。但是当膨胀继续时,球囊的一些其它部分将由于由膨胀流体施加的压力而变形。在一些情况下,球囊变形导致以后球囊缩小的问题。相反,作用在刻划线135上的、指向外的膨胀压力使得可运动SCW端部138向远侧运动,这降低了刻划线135对可膨胀球囊115施加的反作用力。当可运动SCW端部138向远侧运动时,它从毂形部管腔145后退。在一些实施例中,膨胀压力使得可运动SCW端部138从毂形部管腔145拉出。在其它实施例中,可运动SCW端部138保留在毂形部管腔145内。
医师保持膨胀球囊115中的压力足够长时间,以使得刻划线135有医师所希望的效果。然后,医师释放压力,可膨胀球囊115缩小,可运动SCW端部138重新伸入毂形部管腔145中。
图2a至图2c描述了SCB导管100的不同实施例。这些实施例与图1a至1c中所示的实施例类似。在这些组实施例之间的主要区别在于毂形部和近侧刻划线的几何形状。
图2b表示了具有毂形部远侧部分241和毂形部近侧部分242的毂形部140。通过HA逐步降低部分156,毂形部近侧部分242用于使得轴105与手柄组件150连接。另外,毂形部近侧部分242用作弹簧200的止动件。弹簧200包括弹簧线201—附图表示了弹簧线201的截面。弹簧200增加了刻划线135机构的弹性。
毂形部远侧部分241布置在弹簧200的远端附近。毂形部远侧部分241与可运动SCW端部138连接(附接)。在一些实施例中,毂形部远侧部分241固定在可运动SCW端部138上。在其它实施例中,毂形部远侧部分241包括毂形部管腔145,在一些实例中,该毂形部管腔145固定在可运动SCW端部138上。可运动SCW端部138在它到达毂形部远侧部分241时向外张开。在该实施例中,另一方面,图3a至3c中所示的实施例包括可运动SCW端部138,该可运动SCW端部138在它到达毂形部远侧部分241时并不张开。
在由图1a-6公开的装置表示的一组实施例的操作中,医师如上所述布置可膨胀球囊115。医师通过HA 1B管腔端口153使得可膨胀球囊115膨胀,这首先在刻划线135上施加外部压力,然后施加在病变部上。在上述实施例和由图1a-3c所示的实施例组之间的操作差别在于允许通过可运动SCW端部138而运动的机构。如在上述实施例中,在这些实施例中,当可膨胀球囊115膨胀时,否则刻划线135将施加的反作用力由可运动SCW端部138来减轻。在该组中,可运动SCW端部138向远侧后退,如前所述,但是毂形部远侧部分241也向远侧运动。毂形部远侧部分241、弹簧200和毂形部近侧部分242的布置将通过毂形部远侧部分241来向可运动SCW端部138施加力。该力将向近侧偏压可运动SCW端部138。还有,当医师使得球囊缩小时,如前所述,可运动SCW端部138在弹簧200的力的辅助下向近侧运动,基本返回至它的初始位置。
图4a-4b描述了SCB导管100的另一实施例。该实施例的装置与上述实施例基本类似。主要区别在于,该形式的毂形部远侧部分241虽然与上述毂形部远侧部分相似,但是具有从毂形部远侧部分241向近侧延伸的变窄区域340(见图4b)。该变窄区域340位于弹簧200的内部。
类似地,图5a有变窄区域340,且另外有位于毂形部远侧部分241和变窄区域340之间的延伸部分451。手指把手400位于延伸部分451上,其延伸穿过轴近侧部分106的侧部。手指把手400向医师提供了远端毂形部450的一些控制,这使得在这些类型的实施例中能够更直接地控制可运动SCW端部138。
图6公开了装置的近侧部分的实施例。在该实施例中,弹簧200布置在HA 150的远端内,并从HA 150向远侧延伸。毂形部140与HA 150连接,并与HA 150形成单件结构。弹簧200接收轴近侧部分106。参考图1C,能够理解,可运动SCW端部138在轴近侧部分106的远端附近离开刻划线管腔1139。可运动SCW端部138通过任何合适的方法而与弹簧200直接连接,例如钎焊、焊接、覆盖模制、胶接或者使用塑料管来压配合。在一些实施例中,可运动SCW端部138通过焊接接头1362而与弹簧200直接连接。在这个或其它实施例中,毂形部盖700布置在毂形部140和轴105的上面。在一些实例中,毂形部盖700减小了在HA 150和轴105之间的连接的应变。
弹簧200向可运动SCW端部138提供纵向运动和偏压力。当可运动SCW端部138受到指向远侧的力(该力使它向远侧运动)时,该运动使其保持远离HA 150。一旦指向远侧的力消失,恢复力或与向远侧拉伸相对的力(反作用力)就将使得可运动SCW端部138基本返回就位。
图7a描述了图1a的截面BB。它表示了两个刻划线135、可膨胀球囊115、1B管腔133和导丝管腔119。可以看见,截面BB在轴远侧部分108处穿过SCB导管100切开。截面还切开可膨胀球囊115;在SCW IB部分137处切开刻划线135,从而表示了SCW横截面505;还切开导丝管腔119。图7b描述了类似的实施例,但是有三个刻划线135。
图8a描述了图1a的截面AA。它表示了两个并排布置的SCW管腔1139。它还表示了IB管腔133和GW管腔119。SCW管腔1139并不必须采用并排设置,如该图中所示,而是能够采用环绕轴105的周边分布的设置。
图8b表示了与图1a类似的、不同实施例的剖视图。轴近侧部分106在轴锥形部分111的近侧切开。轴锥形部分111从轴近侧部分106向轴中间部分107逐渐变细。轴105具有轴壁109。例如,图8b表示了两个SCW管腔1139,这两个SCW管腔1139在轴105中在彼此对面分布。这种分布不需要是对称的。还在该图中,导丝管腔119布置在轴105内,它表示了在轴105内部纵向延伸的SCW管腔1139。在一些实施例中,SCW管腔布置在导丝管腔的外部。
图9表示了图6的实施例沿线CC的剖视图。在该图中,导丝管腔119布置在轴105内。在一些实施例中,轴105是提供了导丝管腔119、两个SCW管腔1139和一个管腔133的挤出件。
在上述任何实施例中,可膨胀球囊115能够有范围为从1.25-40mm或2.0-8.0mm的任何直径。在上述任何实施例中,可膨胀球囊115能够有例如10-300mm或20-300mm的任何长度。较长球囊可以特别有利于治疗周围病变部,该周围病变部通常具有较长病变部分。
在上述所有系统中,涂层(例如憎水性或亲水性涂层)可以在外部添加,以便容易插入。
合适的药物或治药剂包括以下物质。
抗微生物剂可以例如选自以下:三氯生、氯己定、呋喃西林,苯扎氯铵、银盐和抗生素,例如利福平、庆大霉素和米诺环素及其组合。
在某些实施方案中,抗微生物剂可以包括:三氯生、氯己定以及它们的盐或组合。抗炎剂的实例包括甾体和非甾体抗炎剂。非甾体类抗炎药的实例包括:氨基芳基羧酸衍生物,例如恩芬那酸、依托芬那酯、氟灭酸、异尼辛、甲氯芬那酸、美夫那酸、尼氟灭酸、他尼氟酯、特罗氨酯和托芬那酸;芳基乙酸衍生物,例如阿西美辛、阿氯芬酸、氨基苯酰基苯乙酸、丁苯羟酸、吲朵拉斯、氯吡酸、双氯芬酸钠,依托度酸、联苯乙酸、芬氯酸、苯克洛酸、芬克洛酸、双苯噻酸、葡美辛、异丁芬酸、吲哚美辛、三苯唑酸、伊索克酸、氯苯唑酸、甲嗪酸、奥沙米辛、丙美格辛、舒林酸、羟哌苯酮、托美丁和佐美酸;芳基丁酸衍生物,例如丁丙二苯肼、异丁苯丁酸、芬布芬和联苯丁酸;芳基羧酸,例如环氯茚酸、酮咯酸和替诺立定;芳丙酸衍生物,例如阿米洛芬、苯恶洛芬、布氯酸、卡洛芬、非诺洛芬、氟诺洛芬、氟比洛芬、布洛芬、异丁普生、吲哚洛芬、酮洛芬、氯索洛芬、米洛芬、萘普生、奥沙普秦、吡酮洛芬、吡咯布洛芬、普拉洛芬、丙替嗪酸、舒洛芬和噻洛芬酸;吡唑,例如二苯米唑和甲嘧啶唑;吡唑酮类,例如阿扎丙宗、苄哌吡酮、菲普拉酮、莫非保松、吗拉宗、羟基保泰松、苯基保泰松、哌布宗、异丙安替比林、雷米那酮、琥保松和噻唑丁炎酮;水杨酸及其衍生物,例如醋氨沙罗、阿司匹林、扑炎痛、溴水杨醇、乙酰水杨酸钙、二氟尼柳、依特柳酯、芬达沙、龙胆酸、水杨酸乙二醇酯、水杨酸咪唑、赖氨酸乙酰水杨酸、马沙拉嗪、水杨酸吗啉、1-水杨酸萘酯、奥沙拉秦、帕沙米特、乙酰水杨酸苯酯、水杨酸苯酯、醋水杨胺、水杨酰胺a-乙酸、水杨酰硫酸酯、双水杨酯和柳氮磺胺吡啶;噻嗪甲酰胺,如达洛昔康,异索昔康,吡罗昔康和替诺昔康;其它例如E-6-乙酰氨基己酸、s-腺苷甲硫氨酸、3-氨基-4-羟基丁酸、阿米曲林、苄达酸、炎痛静、布可隆、吡啶基联苯基乙酰胺、双苯吡醇、依莫法宗、愈创奥、萘布美酮、尼美舒利、肝蛋白、奥沙西罗、瑞尼托林、吡哆醛、哌福肟、普罗喹宗、普罗沙唑和替尼达帕;以及它们在药学上可接受的盐。
甾体抗炎剂(糖皮质激素)的实例包括21-乙酰氧普诺烯酮、阿氯米松、阿尔孕酮、阿米西奈德、倍氯米松、倍他米松、布地奈德、氯泼尼松、氯倍他索、氯倍他松、氯可托龙、氯苯尼醇、皮质酮、醋酸皮质酮、可的伐唑、地夫可特、地萘德、去羟米松、地塞米松、二氟松、氟米松、二氟泼尼酯、甘草次酸、氟扎卡松、氟氯萘德、氟地塞米松、氟尼缩松、氟轻松、氟轻松醋酸酯、氟可丁、氟可龙、氟米龙、醋酸氟培龙、醋酸氟泼尼定、氟泼尼龙、氟氢缩松、丙酸氟替卡松、氟甲酰龙、哈西缩松、卤倍他素原阿片、卤米松、醋酸卤泼尼松、氢化可的松、皮脂醇、氯替泼诺碳酸乙酯、马来尼酮、甲羟松、甲泼尼松、甲强龙、莫米松糠酸酯、帕拉米松、泼尼卡酯、泼尼松龙、泼尼松龙25-二乙基氨基乙酸酯、泼尼松磷酸钠、泼尼松、泼尼松龙戊酸酯、泼尼立定、双甲丙酰龙、替克索醇、去炎松、曲安奈德、苯曲安缩松、己曲安缩松以及它们在药学上可接受的盐。
止痛剂包括麻醉和非麻醉止痛剂。麻醉止痛剂包括阿芬太尼、烯丙罗定、阿法罗丁、氨苄杜冷丁、苄吗啡、苯腈米特、丁丙诺啡、布托啡诺、氯尼他秦、可待因、溴甲可待因、磷酸可待因、硫酸可待因、二氢脱氧吗啡、右旋吗酰胺、地佐辛、双胺丙酰胺、二氢可待因、二氢可待因酮烯醇乙酸酯、二氢吗啡、地美沙多、美沙醇、二甲噻丁、吗苯丁酯、地匹哌酮、依他佐辛、乙庚嗪、依托尼秦、乙基吗啡、乙氧硝唑、芬太尼、氢可酮、氢吗啡酮、羟哌替啶、异美沙酮、凯托米酮、羟甲左吗南、洛芬太尼、度冷丁、美普他酚、美他佐辛、盐酸持杀酮、麦托朋、吗啡、麦罗啡、纳布啡、那碎因、尼可吗啡、去甲左啡醇、去甲美沙酮、去甲吗啡、诺匹哌酮、鸦片、羟可酮、氧吗啡酮、阿片全碱、镇痛新、非那多栓、非那左辛、间氨基苯乙醚、去痛定、哌腈米特、普罗庚嗪、二甲哌替啶、异丙哌替胺、丙吡胺丙氧吩、雷米芬太尼、舒芬太尼、替利定、以及它们在药学上可接受的盐。非麻醉止痛剂包括醋氯芬酸、对乙酰氨基酚、醋氨沙罗、乙酰苯胺、乙酰水杨酰水杨酸、阿氯芬酸、阿米洛芬、阿洛泼林、双(乙酰水杨酸)铝、氨氯苯嗪、2-氨基-4-甲基吡啶、氨丙吡酮、氨基比林、水杨酸铵、呱氨托美丁、安替比林、水杨酸安替比林、安曲非宁、阿扎丙宗、阿司匹林、扑炎痛、苯恶洛芬、苄哌吡酮、炎痛静、拜莫洛芬、溴芬酸、对溴乙酰苯胺、5-溴水杨酸乙酸酯、布西丁、丁苯羟酸、丁丙二苯肼、布他西丁、乙酰水杨酸钙、氨甲酰氮草、卡比芬、卡沙兰、氯醛比林、氯西诺嗪、胆碱水杨酸盐、阿托方、西拉马多、氯美辛、巴酰丙酰胺、克罗乙胺、右苯恶啶、二苯米唑、二氟苯水杨酸、乙酰水杨酸二羟铝、地匹乙酯、安乃近、依莫法宗、苯乙氨茴酸、甲嘧啶唑、乙氧基扑炎痛、乙柳酰胺、依托沙秦、依托度酸、联苯乙酸、非诺洛芬、夫洛非宁、氟芬那酸、氟苯乙砜、氟吡汀、氟丙喹酮、氟比洛芬、磷柳酸、龙胆酸、格拉非宁、异丁苯乙酸、水杨酸咪唑、吲哚辛、吲哚洛芬、三苯唑酸、异甲丙基二硝基苯酚(isoladol)、异尼克辛、酮洛芬、酮洛酸、对乙氧乳酰苯胺、来苯胺、氯索洛芬、赖氨酸乙酰水杨酸、乙酰水杨酸镁、甲氧异丙嗪、甲氧夫啉、咪洛芬、吗拉宗、水杨酸吗啉、甲氧萘丙酸、奈福泮、烟胺比林、5′硝基-2′羟基乙酰苯胺、帕沙米特、吡哆醛、非那西汀、盐酸非那吡啶、非诺可、非诺吡酮、乙酰水杨酸苯酯、水杨酸苯酯、非尼拉朵、哌布宗、哌立酮、普罗利定、丙帕他莫、异丙安替比林、普罗沙唑、水杨酸奎宁、雷米那酮、利马唑甲硫酸盐、醋水杨胺、水杨苷、水杨酰胺、水杨酰胺a-乙酸、水杨酸硫酸酯、双水杨酯、沙维林、西美曲特、水杨酸钠、磺甲比林、舒洛芬、他尼氟酯、替诺昔康、特罗氨酯、粉防已碱、替诺立定、托芬那酸、托普罗宁、曲马多、维米醇、联苯乙酸、佐美酸以及它们在药学上可接受的盐。
局部麻醉剂包括羟乙卡因、阿莫拉酮、盐酸阿米洛卡因、奥布卡因、苯佐卡因、贝托卡因、苯柳胺酯、丁哌卡因、布他卡因、布坦本、布坦卡因、丁胺卡因、丁托西卡因、卡铁卡因、氯普鲁、卡因、可卡乙碱、可卡因、环美卡因、盐酸辛可卡因、奎尼卡因、二甲卡因、盐酸地培酮、达克罗宁、芽子定、芽子碱、氯乙烷、β-优卡因、尤普罗辛、非那可明、福吗卡因、盐酸己卡因、羟丁卡因、对氨苯酸异丁酯、甲磺酸亮氨卡因、左苯恶啶、利多卡因、甲哌卡因、美普卡因、美布卡因、氯甲烷、麦替卡因、纳依卡因、辛卡因、奥索卡因、奥昔卡因、对乙氧卡因、非那卡因、苯酚、皮珀罗卡因、匹多卡因、聚多卡醇、普莫卡因、丙胺卡因、普鲁卡因、丙泮卡因、丙美卡因、丙哌卡因、丙氧卡因盐酸盐、假可卡因、吡咯卡因、罗哌卡因、水杨醇、盐酸丁卡因、托利卡因、美索卡因、佐拉敏以及它们在药学上可接受的盐。
抗痉挛剂包括阿利苯多、氨布醋胺、氨丙嗪、阿托胺、贝弗宁甲硫酸盐、比坦维林、苯哌丙丁酯、溴丁托品、溴丁东莨菪碱、卡罗维林、西托溴铵、桂麻磺碱、氯波必利、氢溴酸欧毒芹硷、盐酸欧毒芹硷、碘化环宁、双苯美林、地索普明、吗苯丁酯、地泼溴铵、六氢芬宁、溴苯丁乙甲铵、依他维林、非克立明、非诺维林、二苯丙哌啶、苯维溴铵、芬托溴铵、黄酮哌酯、三羟苯丙酮、葡萄糖酸、愈创他明、肼双二乙氨三嗪、羟甲氧色烯、利奥吡咯、美贝维林、莫沙维林、萘维林、辛戊胺、奥他维林、盐酸羟丁宁、戊派啶酯、盐酸苯那米特、间苯三酚、匹维溴胺、哌苯乙醇、盐酸哌泊索仑、普拉维林、吡芬溴铵、异丙哌替啶、普鲁匹凡、吡吗嗪、普罗扎平、消旋非明、罗西维林、解挛醚、司洛碘铵、舒托泊铵、替莫碘铵、替喹溴铵、苯酰胺桂胺、三乙丁酮、3-甲色酮、三叶草、曲美布汀、n,n-1三甲基色氨酸-3,3-苯基苯-丙胺、齐酸甲氧托品、曲司氯铵、珍托溴铵以及它们在药学上可接受的盐。
在某些实施方案中,用于减轻疼痛或不适的治疗剂可以选自酮咯酸以及它们在药学上可接受的盐(例如氨丁三醇盐,商品名为),4-二乙基氨基-2-苯环己基乙醇丁酯以及它们在药学上可接受的盐(例如4-二乙基氨基-2-苯环己基乙醇酸丁酯盐酸盐,也称为氯化奥昔布宁,商品名为)以及它们的组合。存在的治疗剂的量将取决于例如所用治疗剂的功效,释放速率等。本领域技术人员可以容易地确定合适的治疗剂加载量,以便实现所希望的结果。
在一些实施例中,IB 115的表面压花成具有任何图案。例如,在一些实施例中,IB115的表面压花成具有方格图案。另外,在一些实施例中,可膨胀球囊115沿它的纵向方向逐渐变细。
在一些实施例中,刻划线135布置在SCW管腔1139内。且在一些实施例中,SCW管腔1139布置在轴105的外部。
尽管已经结合具体实施例介绍了本发明,但是本领域技术人员将清楚许多替代、改变和变化。因此,本发明包含落入附加权利要求的精神和范围内的所有这些替代、改变和变化。本说明书中提及的所有出版物、专利和专利申请都整个被本文参引,就像各出版物、专利或专利申请具体和单独地包含在本文中。另外,本申请中任何参考文献的引用或标识不应当解释为承认该参考文献可用作本发明的现有技术。
Claims (10)
1.一种刻划球囊导管,包括:
轴,所述轴包括远侧区域、远端和近端;
可膨胀的球囊,所述可膨胀的球囊安装在轴的远侧区域处;
具有远端和近端的膨胀管腔,其中,所述膨胀管腔的远端在球囊的内部结束;
导丝管腔,所述导丝管腔布置在轴的内部;
手柄,所述手柄安装在轴的近端处,所述手柄具有:
导丝端口,所述导丝端口连接至导丝管腔的近端;和
球囊膨胀端口,所述球囊膨胀端口连接至膨胀管腔的近端;
弹簧,所述弹簧在手柄的远端处同轴地安装在所述轴的内部,所述弹簧具有远侧区域;
至少两个刻划线管腔,所述刻划线管腔在轴的内部彼此靠近地设置在轴的一侧,靠近导丝管腔,具有在球囊的近侧开始的远端和在弹簧的远侧结束的近端;
至少两个刻划线,每个刻划线都在一个刻划线管腔内,所述刻划线具有:
安装在轴上且位于轴的远端和球囊之间的端部;
中间部分,所述中间部分沿纵向追踪球囊的外部;
近侧部分,所述近侧部分位于刻划线管腔的内部;以及
固定在弹簧上的近端。
2.根据权利要求1所述的刻划球囊导管,其中:所述轴由聚合物制成。
3.根据权利要求1或2所述的刻划球囊导管,其中:两个刻划线的近端焊接在弹簧上。
4.根据权利要求1-3中任一项所述的刻划球囊导管,其中:所述弹簧布置成施加偏压力,所述偏压力作用成对抗至少一个、优选是两个刻划线的近端向远侧的运动。
5.根据权利要求1、2或4所述的刻划球囊导管,其中:两个刻划线的近端通过钎焊、焊接、覆盖模制、胶接或者使用塑料管来压配合中的一种固定在弹簧上。
6.根据权利要求1所述的刻划球囊导管,还包括毂形部,其中:弹簧布置成环绕轴,并局部地在毂形部内。
7.根据权利要求6所述的刻划球囊导管,其中:近端附接在弹簧的外表面上。
8.根据权利要求7所述的刻划球囊导管,还包括两个至八个刻划线,其中:各管腔与一个或多个刻划线相连,所述刻划线优选是容纳在相连的管腔内。
9.根据权利要求8所述的刻划球囊导管,还包括用于各刻划线的管腔。
10.根据权利要求9所述的刻划球囊导管,其中:近端向外逐渐倾斜。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562249119P | 2015-10-30 | 2015-10-30 | |
US62/249,119 | 2015-10-30 | ||
US15/210,603 US10561438B2 (en) | 2015-10-30 | 2016-07-14 | Scoring balloon with translating scoring wires |
US15/210,603 | 2016-07-14 | ||
PCT/US2016/059537 WO2017075502A1 (en) | 2015-10-30 | 2016-10-28 | Scoring balloon with translating scoring wires |
CN201680069881.XA CN108289697B (zh) | 2015-10-30 | 2016-10-28 | 具有平移刻划线的刻划球囊 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680069881.XA Division CN108289697B (zh) | 2015-10-30 | 2016-10-28 | 具有平移刻划线的刻划球囊 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114795402A true CN114795402A (zh) | 2022-07-29 |
Family
ID=57389514
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210438822.2A Pending CN114795402A (zh) | 2015-10-30 | 2016-10-28 | 具有平移刻划线的刻划球囊 |
CN201680069881.XA Active CN108289697B (zh) | 2015-10-30 | 2016-10-28 | 具有平移刻划线的刻划球囊 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680069881.XA Active CN108289697B (zh) | 2015-10-30 | 2016-10-28 | 具有平移刻划线的刻划球囊 |
Country Status (7)
Country | Link |
---|---|
US (3) | US10561438B2 (zh) |
EP (3) | EP3560443B1 (zh) |
JP (2) | JP6927967B2 (zh) |
CN (2) | CN114795402A (zh) |
CA (1) | CA3003451C (zh) |
ES (1) | ES2952596T3 (zh) |
WO (1) | WO2017075502A1 (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11660439B2 (en) | 2015-07-02 | 2023-05-30 | Covellus Llc | Modular medical device system |
US10912922B2 (en) | 2015-07-02 | 2021-02-09 | Covellus Llc | Modular medical device catheter system |
US10814120B2 (en) | 2015-07-02 | 2020-10-27 | Covellus Llc | Modular medical device catheter system |
US12082845B2 (en) | 2015-09-04 | 2024-09-10 | The Trustees Of The University Of Pennsylvania | Systems and methods for percutaneous removal of objects from an internal body space |
US11051853B2 (en) | 2015-09-04 | 2021-07-06 | The Trustees Of The University Of Pennsylvania | Systems and methods for percutaneous removal of objects from an internal body space |
US10531890B2 (en) * | 2016-12-30 | 2020-01-14 | C.R. Bard, Inc. | Scoring balloon with translating scoring wires |
WO2021213624A1 (de) * | 2020-04-20 | 2021-10-28 | Ev Group E. Thallner Gmbh | Verfahren und vorrichtung zum transferieren einer übertragungsschicht |
US20230201533A1 (en) | 2020-06-10 | 2023-06-29 | C.R. Bard, Inc. | Scoring balloon catheter with enhanced pushability and maneuverability |
EP4175706A1 (en) | 2020-07-03 | 2023-05-10 | Clearstream Technologies Limited | Medical device for dilating an endovascular lumen |
US20240149020A1 (en) * | 2022-11-04 | 2024-05-09 | Controlled Delivery Systems, Inc. | Catheters for the aspiration controlled delivery of closure agents |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4273128A (en) * | 1980-01-14 | 1981-06-16 | Lary Banning G | Coronary cutting and dilating instrument |
US5904679A (en) * | 1989-01-18 | 1999-05-18 | Applied Medical Resources Corporation | Catheter with electrosurgical cutter |
US20100010521A1 (en) * | 2008-07-10 | 2010-01-14 | Cook Incorporated | Cutting balloon with movable member |
CN201564947U (zh) * | 2009-10-30 | 2010-09-01 | 业聚医疗器械(深圳)有限公司 | 球囊导管 |
CN102083376A (zh) * | 2008-06-10 | 2011-06-01 | 巴伐利亚医药技术股份有限公司 | 用于治疗患病心脏瓣膜的刻划导管 |
EP2438882A1 (en) * | 2010-10-06 | 2012-04-11 | Rex Medical, L.P. | Cutting wire assembly for use with a catheter |
CN103949002A (zh) * | 2014-05-04 | 2014-07-30 | 广东博迈医疗器械有限公司 | 一种单导丝切割球囊导管 |
US20140277002A1 (en) * | 2013-03-13 | 2014-09-18 | The Spectranetics Corporation | Assisted cutting balloon |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5779698A (en) * | 1989-01-18 | 1998-07-14 | Applied Medical Resources Corporation | Angioplasty catheter system and method for making same |
DE69126780T2 (de) | 1990-05-11 | 1998-02-19 | Applied Medical Resources, Inc., Laguna Hills, Calif. | Dilatationskathetereinheit mit schneideelement |
CA2052310A1 (en) | 1990-10-09 | 1992-04-10 | Thomas L. Foster | Surgical access sheath |
US5624449A (en) | 1993-11-03 | 1997-04-29 | Target Therapeutics | Electrolytically severable joint for endovascular embolic devices |
DE69821127T2 (de) | 1997-02-13 | 2004-06-09 | Boston Scientific Ltd., St. Michael | Perkutane und hiatale geräte zur verwendung bei minimal invasiver beckenchirurgie |
US5722979A (en) | 1997-04-08 | 1998-03-03 | Schneider (Usa) Inc. | Pressure assisted ultrasonic balloon catheter and method of using same |
WO1998053616A1 (de) | 1997-05-16 | 1998-11-26 | Christoph Grossmann | Autostereoskopische displayvorrichtung |
US6013052A (en) * | 1997-09-04 | 2000-01-11 | Ep Technologies, Inc. | Catheter and piston-type actuation device for use with same |
US6517515B1 (en) * | 1998-03-04 | 2003-02-11 | Scimed Life Systems, Inc. | Catheter having variable size guide wire lumen |
WO1999059667A1 (en) | 1998-05-15 | 1999-11-25 | Medgination, Inc. | Enhanced balloon dilatation system |
US20040034384A1 (en) | 2001-08-08 | 2004-02-19 | Kohei Fukaya | Expansion catheter |
US7029450B2 (en) * | 2001-12-14 | 2006-04-18 | Boston Scientific Scimed, Inc. | Dilation catheter assembly and related methods |
US7186237B2 (en) | 2002-02-14 | 2007-03-06 | Avantec Vascular Corporation | Ballon catheter for creating a longitudinal channel in a lesion and method |
JP2004267323A (ja) | 2003-03-06 | 2004-09-30 | Nipro Corp | 留置針組立体 |
US7708753B2 (en) * | 2005-09-27 | 2010-05-04 | Cook Incorporated | Balloon catheter with extendable dilation wire |
US7901378B2 (en) | 2006-05-11 | 2011-03-08 | Y-Med, Inc. | Systems and methods for treating a vessel using focused force |
US20080114364A1 (en) * | 2006-11-15 | 2008-05-15 | Aoi Medical, Inc. | Tissue cavitation device and method |
US8945160B2 (en) | 2008-07-03 | 2015-02-03 | Hotspur Technologies, Inc. | Apparatus and methods for treating obstructions within body lumens |
AU2010275430B2 (en) * | 2009-07-23 | 2015-11-26 | Arrow International, Inc. | Apparatus and methods for treating obstructions within body lumens |
CN201596232U (zh) * | 2009-12-28 | 2010-10-06 | 业聚医疗器械(深圳)有限公司 | 球囊导管 |
EP2593170A1 (en) * | 2010-07-16 | 2013-05-22 | Abbott Cardiovascular Systems Inc. | Medical device having tissue engaging member and method for delivery of a therapeutic agent |
US9282991B2 (en) | 2010-10-06 | 2016-03-15 | Rex Medical, L.P. | Cutting wire assembly with coating for use with a catheter |
JP2012196321A (ja) | 2011-03-22 | 2012-10-18 | Nipro Corp | バルーンカテーテル |
US9005196B2 (en) * | 2011-08-16 | 2015-04-14 | Boston Scientific Scimed, Inc. | Medical device handles and related methods of use |
EP2870936B1 (en) | 2013-11-07 | 2016-10-26 | Cook Medical Technologies LLC | Balloon catheter with lithotripsy amplification system |
US9526518B2 (en) * | 2014-03-28 | 2016-12-27 | Ethicon Endo-Surgery, Llc | Surgical cutting devices and methods that include a self-adjusting cutting blade |
EP3213699A4 (en) * | 2014-10-27 | 2018-04-18 | Terumo Kabushiki Kaisha | Medical device |
-
2016
- 2016-07-14 US US15/210,603 patent/US10561438B2/en active Active
- 2016-10-28 EP EP19179945.1A patent/EP3560443B1/en active Active
- 2016-10-28 CN CN202210438822.2A patent/CN114795402A/zh active Pending
- 2016-10-28 ES ES21161247T patent/ES2952596T3/es active Active
- 2016-10-28 WO PCT/US2016/059537 patent/WO2017075502A1/en active Application Filing
- 2016-10-28 JP JP2018522522A patent/JP6927967B2/ja active Active
- 2016-10-28 CA CA3003451A patent/CA3003451C/en active Active
- 2016-10-28 CN CN201680069881.XA patent/CN108289697B/zh active Active
- 2016-10-28 EP EP21161247.8A patent/EP3884886B1/en active Active
- 2016-10-28 EP EP16798862.5A patent/EP3367935B1/en active Active
-
2020
- 2020-01-17 US US16/745,765 patent/US11771457B2/en active Active
-
2021
- 2021-08-05 JP JP2021128766A patent/JP7324806B2/ja active Active
-
2023
- 2023-08-16 US US18/234,665 patent/US20230389955A1/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4273128A (en) * | 1980-01-14 | 1981-06-16 | Lary Banning G | Coronary cutting and dilating instrument |
US5904679A (en) * | 1989-01-18 | 1999-05-18 | Applied Medical Resources Corporation | Catheter with electrosurgical cutter |
CN102083376A (zh) * | 2008-06-10 | 2011-06-01 | 巴伐利亚医药技术股份有限公司 | 用于治疗患病心脏瓣膜的刻划导管 |
US20100010521A1 (en) * | 2008-07-10 | 2010-01-14 | Cook Incorporated | Cutting balloon with movable member |
CN201564947U (zh) * | 2009-10-30 | 2010-09-01 | 业聚医疗器械(深圳)有限公司 | 球囊导管 |
EP2438882A1 (en) * | 2010-10-06 | 2012-04-11 | Rex Medical, L.P. | Cutting wire assembly for use with a catheter |
US20140277002A1 (en) * | 2013-03-13 | 2014-09-18 | The Spectranetics Corporation | Assisted cutting balloon |
CN103949002A (zh) * | 2014-05-04 | 2014-07-30 | 广东博迈医疗器械有限公司 | 一种单导丝切割球囊导管 |
Also Published As
Publication number | Publication date |
---|---|
US11771457B2 (en) | 2023-10-03 |
EP3560443A1 (en) | 2019-10-30 |
JP6927967B2 (ja) | 2021-09-01 |
CN108289697A (zh) | 2018-07-17 |
EP3884886A1 (en) | 2021-09-29 |
EP3884886C0 (en) | 2023-08-02 |
EP3560443B1 (en) | 2021-03-10 |
JP2018535006A (ja) | 2018-11-29 |
EP3367935B1 (en) | 2019-08-07 |
US20230389955A1 (en) | 2023-12-07 |
CA3003451A1 (en) | 2017-05-04 |
US10561438B2 (en) | 2020-02-18 |
EP3367935A1 (en) | 2018-09-05 |
WO2017075502A1 (en) | 2017-05-04 |
ES2952596T3 (es) | 2023-11-02 |
US20200146710A1 (en) | 2020-05-14 |
EP3884886B1 (en) | 2023-08-02 |
CN108289697B (zh) | 2023-02-28 |
CA3003451C (en) | 2023-12-12 |
JP2021183158A (ja) | 2021-12-02 |
JP7324806B2 (ja) | 2023-08-10 |
US20170119428A1 (en) | 2017-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114795402A (zh) | 具有平移刻划线的刻划球囊 | |
JP7224287B2 (ja) | 並進スコアリングワイヤを備えたスコアリングバルーン | |
JP6943840B2 (ja) | 洞および鼻のステント | |
JP2023134620A (ja) | トレプロスチニルおよびその塩の皮膚投与および経皮投与方法 | |
US10130385B2 (en) | Method and apparatus for placing a catheter within a vasculature | |
US20140249511A1 (en) | Catheter apparatus and methods for treating vasculatures | |
US20090105719A1 (en) | Precision stent positioner | |
US10159822B2 (en) | Catheter and treatment methods for lower leg ischemia | |
US20150151090A1 (en) | Coaxial guide coil for interventional cardiology procedures | |
WO2007103113A3 (en) | Dosage forms for administering combinations of drugs | |
WO2011139595A3 (en) | Elongated biodegradable depot for sustained drug release to treat chronic pelvic pain | |
WO2007008784A3 (en) | Medical device balloon | |
JP2016514004A (ja) | 組織再活性化のための装置及び方法 | |
WO2012003484A3 (en) | Catheter for use in revascularization procedures and method of using same | |
CN104955516A (zh) | 延长丁丙诺啡经皮递送组合物及其使用方法 | |
KR100822866B1 (ko) | 약제 첨가된 랩 | |
JP2023537183A (ja) | 精密な薬剤溶出機能を備えたバルーンカテーテル | |
CN115996686B (zh) | 包括可扩张肌肉聚合物的医疗装置 | |
US20150306360A1 (en) | Rotational Localized Drug Delivery Device | |
US20210007903A1 (en) | Analgesic Nose Plugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |